{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:34:48Z","timestamp":1791462888178,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1 DA050067"],"award-info":[{"award-number":["UG1 DA050067"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3 DA0044830-02S1"],"award-info":[{"award-number":["UG3 DA0044830-02S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005267","name":"Center for Substance Abuse Treatment","doi-asserted-by":"publisher","award":["1H79T1081387-01"],"award-info":[{"award-number":["1H79T1081387-01"]}],"id":[{"id":"10.13039\/100005267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001146","name":"Greenwall Foundation","doi-asserted-by":"publisher","award":["UG3 DA0044830-02S1"],"award-info":[{"award-number":["UG3 DA0044830-02S1"]}],"id":[{"id":"10.13039\/100001146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001146","name":"Greenwall Foundation","doi-asserted-by":"publisher","award":["UG1 DA050067"],"award-info":[{"award-number":["UG1 DA050067"]}],"id":[{"id":"10.13039\/100001146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jsat.2019.08.002","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T01:51:18Z","timestamp":1565142678000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2\u202fyears: Results from a multisite randomized trial of adults with opioid use disorder"],"prefix":"10.1016","volume":"106","author":[{"given":"Elizabeth A.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ing","family":"Hser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.08.002_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2019.08.002_bb0010","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"issue":"10182","key":"10.1016\/j.jsat.2019.08.002_bb0015","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2019.08.002_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0027-9684(15)30175-9","article-title":"Opioid addiction and abuse in primary care practice: A comparison of methadone and buprenorphine as treatment options","volume":"104","author":"Bonhomme","year":"2012","journal-title":"Journal of the National Medical Association"},{"key":"10.1016\/j.jsat.2019.08.002_bb0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.08.002_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.jsat.2019.08.002_bb0035","first-page":"3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians","volume":"15","author":"DeFlavio","year":"2015","journal-title":"Rural and Remote Health"},{"key":"10.1016\/j.jsat.2019.08.002_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.08.002_bb0045","doi-asserted-by":"crossref","unstructured":"Evans, E.A., Hser, YI., 2019. The natural history, clinical course, and long-term recovery from opioid use disorders. In Kelly and Wakeman (editors), Treating opioid addiction. Humana Press, Springer International. https:\/\/doi.org\/10.1007\/978-3-030-16257-3_9.","DOI":"10.1007\/978-3-030-16257-3_9"},{"key":"10.1016\/j.jsat.2019.08.002_bb0050","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006\u201310","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.08.002_bb0055","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14620","article-title":"Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder","volume":"114","author":"Evans","year":"2019","journal-title":"Addiction. In press."},{"key":"10.1016\/j.jsat.2019.08.002_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/08897077.2013.819828","article-title":"A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment","volume":"35","author":"Fingerhood","year":"2014","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2019.08.002_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1521-0391.2012.12004.x","article-title":"Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system","volume":"22","author":"Gryczynski","year":"2013","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2019.08.002_bb0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2012.12.008","article-title":"Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes","volume":"131","author":"Haddad","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.08.002_bb0075","series-title":"Drug overdose deaths in the United States, 1999\u20132016","author":"Hedegaard","year":"2017"},{"key":"10.1016\/j.jsat.2019.08.002_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1037\/1040-3590.4.2.207","article-title":"Reliability of retrospective self-report by narcotics addicts","volume":"4","author":"Hser","year":"1992","journal-title":"Psychological Assessment"},{"key":"10.1016\/j.jsat.2019.08.002_bb0085","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.08.002_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/ADM.0000000000000274","article-title":"Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine\u202f+\u202fnaloxone and methadone","volume":"11","author":"Hser","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.08.002_bb0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/0193841X07307316","article-title":"The life course perspective on drug use: A conceptual framework for understanding drug use trajectories","volume":"31","author":"Hser","year":"2007","journal-title":"Evaluation Review"},{"key":"10.1016\/j.jsat.2019.08.002_bb0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1741-3737.2011.00861.x","article-title":"Toward best practices in analyzing datasets with missing data: Comparisons and recommendations","volume":"73","author":"Johnson","year":"2011","journal-title":"Journal of Marriage and the Family"},{"key":"10.1016\/j.jsat.2019.08.002_bb0105","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2019.08.002_bb0110","series-title":"Mortality in the United States, 2016., NCHS data brief","author":"Kochanek","year":"2017"},{"key":"10.1016\/j.jsat.2019.08.002_bb0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1176\/appi.ajp.2014.14081014","article-title":"Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: A randomized controlled trial with ecological momentary assessment","volume":"172","author":"Kowalczyk","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.08.002_bb0120","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2014.955469","article-title":"Buprenorphine in the treatment of opioid addiction: Opportunities, challenges and strategies","volume":"15","author":"Li","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.jsat.2019.08.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.08.002_bb0130","series-title":"Cochrane database of systematic reviews","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2008"},{"key":"10.1016\/j.jsat.2019.08.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-015-0009-2","article-title":"Implementing buprenorphine in addiction treatment: Payer and provider perspectives in Ohio","volume":"10","author":"Molfenter","year":"2015","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2019.08.002_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/002204261004000210","article-title":"Self-report of longitudinal substance use: A comparison of the UCLA natural history interview and the addiction severity index","volume":"40","author":"Murphy","year":"2010","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.jsat.2019.08.002_bb0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.08.002_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drugalcdep.2014.07.020","article-title":"Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991\u20132012","volume":"143","author":"Nosyk","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.08.002_bb0155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1037\/a0037550","article-title":"A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: Findings from a retrospective multisite study","volume":"22","author":"Proctor","year":"2014","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2019.08.002_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2019.08.002_bb0165","series-title":"SAS Enterprise Guide 5.1","author":"SAS Institute Inc.","year":"2013"},{"key":"10.1016\/j.jsat.2019.08.002_bb0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: A randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.08.002_bb0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"The Annals of Statistics"},{"key":"10.1016\/j.jsat.2019.08.002_bb0180","series-title":"Measuring alcohol consumption","first-page":"41","article-title":"Timeline follow-back: A technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.jsat.2019.08.002_bb0185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties","volume":"93","author":"Stein","year":"2015","journal-title":"The Milbank Quarterly"},{"key":"10.1016\/j.jsat.2019.08.002_bb0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02791072.2014.921743","article-title":"Patient perspectives on buprenorphine\/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study","volume":"46","author":"Teruya","year":"2014","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2019.08.002_bb0195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2019.08.002_bb0200","series-title":"Facing addiction in America: The surgeon general's report on alcohol, drugs, and health","author":"U.S. Department of Health and Human Services (HHS), O. of the S.G","year":"2016"},{"key":"10.1016\/j.jsat.2019.08.002_bb0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1467-9531.2009.01215.x","article-title":"How to impute interactions, squares, and other transformed variables","volume":"39","author":"von Hippel","year":"2009","journal-title":"Sociological Methodology"},{"key":"10.1016\/j.jsat.2019.08.002_bb0210","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2019.08.002_bb0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.08.002_bb0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.jsat.2019.08.002_bb0225","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial","volume":"66","author":"Woody","year":"2014","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.jsat.2019.08.002_bb0230","series-title":"Multiple imputation for missing data: Concepts and new development (version 9.0)","author":"Yuan","year":"2010"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219302752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219302752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:34:25Z","timestamp":1778506465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219302752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":46,"alternative-id":["S0740547219302752"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.08.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2\u202fyears: Results from a multisite randomized trial of adults with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}